BidaskClub Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to “Sell”

BidaskClub upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong sell rating to a sell rating in a research report report published on Saturday morning, BidAskClub reports.

Several other equities research analysts have also recently weighed in on REGN. ValuEngine upgraded Regeneron Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, May 23rd. BMO Capital Markets lowered their target price on Regeneron Pharmaceuticals from $412.00 to $375.00 and set a market perform rating for the company in a report on Wednesday, May 8th. TheStreet cut Regeneron Pharmaceuticals from a b- rating to a c+ rating in a report on Wednesday, June 5th. Citigroup lowered their target price on Regeneron Pharmaceuticals from $396.00 to $340.00 and set a neutral rating for the company in a report on Thursday, May 23rd. Finally, UBS Group lowered their target price on Regeneron Pharmaceuticals from $480.00 to $440.00 and set a buy rating for the company in a report on Wednesday, May 8th. Three research analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $395.78.

Shares of REGN stock opened at $312.90 on Friday. Regeneron Pharmaceuticals has a twelve month low of $295.27 and a twelve month high of $442.00. The stock has a market cap of $34.51 billion, a PE ratio of 15.80, a price-to-earnings-growth ratio of 1.50 and a beta of 1.13. The stock has a fifty day moving average price of $309.56. The company has a quick ratio of 3.78, a current ratio of 4.58 and a debt-to-equity ratio of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $5.24 by ($0.79). Regeneron Pharmaceuticals had a return on equity of 26.95% and a net margin of 35.13%. The firm had revenue of $1.71 billion during the quarter, compared to analysts’ expectations of $1.76 billion. During the same quarter in the prior year, the company posted $4.67 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 13.3% compared to the same quarter last year. Analysts forecast that Regeneron Pharmaceuticals will post 18.37 EPS for the current fiscal year.

In other news, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $305.93, for a total value of $305,930.00. Following the completion of the transaction, the director now directly owns 11,323 shares of the company’s stock, valued at approximately $3,464,045.39. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Neil Stahl sold 9,853 shares of the business’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $305.74, for a total value of $3,012,456.22. Following the completion of the transaction, the executive vice president now directly owns 47,450 shares of the company’s stock, valued at $14,507,363. The disclosure for this sale can be found here. Insiders own 11.84% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. increased its position in Regeneron Pharmaceuticals by 1.9% during the 1st quarter. BlackRock Inc. now owns 6,042,908 shares of the biopharmaceutical company’s stock valued at $2,481,339,000 after buying an additional 113,683 shares in the last quarter. Vanguard Group Inc increased its position in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. Vanguard Group Inc now owns 5,754,927 shares of the biopharmaceutical company’s stock valued at $2,325,220,000 after buying an additional 75,868 shares in the last quarter. FMR LLC increased its position in Regeneron Pharmaceuticals by 6.6% during the 4th quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock valued at $1,997,245,000 after buying an additional 330,875 shares in the last quarter. Geode Capital Management LLC increased its position in Regeneron Pharmaceuticals by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 1,078,453 shares of the biopharmaceutical company’s stock valued at $402,138,000 after buying an additional 78,143 shares in the last quarter. Finally, American Century Companies Inc. increased its position in Regeneron Pharmaceuticals by 3.7% during the 1st quarter. American Century Companies Inc. now owns 1,041,044 shares of the biopharmaceutical company’s stock valued at $427,473,000 after buying an additional 37,573 shares in the last quarter. 66.91% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: Blockchain

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.